Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.